Regencell Bioscience Holdings Stock Fundamentals
| RGC Stock | USD 5.65 0.05 0.88% |
Regencell Bioscience Holdings fundamentals help investors to digest information that contributes to Regencell Bioscience's financial success or failures. It also enables traders to predict the movement of Regencell Stock. The fundamental analysis module provides a way to measure Regencell Bioscience's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Regencell Bioscience stock.
At present, Regencell Bioscience's Selling And Marketing Expenses is projected to increase significantly based on the last few years of reporting. The current year's Research Development is expected to grow to about 1.1 M, whereas Depreciation And Amortization is forecasted to decline to about 708.3 K. Regencell | Select Account or Indicator |
Regencell Bioscience Holdings Company Return On Equity Analysis
Regencell Bioscience's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Regencell Bioscience Return On Equity | -0.43 |
Most of Regencell Bioscience's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Regencell Bioscience Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Regencell Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Regencell Bioscience Holdings has a Return On Equity of -0.4318. This is 98.2% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The return on equity for all United States stocks is 39.29% higher than that of the company.
Regencell Bioscience Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Regencell Bioscience's current stock value. Our valuation model uses many indicators to compare Regencell Bioscience value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Regencell Bioscience competition to find correlations between indicators driving Regencell Bioscience's intrinsic value. More Info.Regencell Bioscience Holdings is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Regencell Bioscience's Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Regencell Bioscience's earnings, one of the primary drivers of an investment's value.Regencell Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Regencell Bioscience's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Regencell Bioscience could also be used in its relative valuation, which is a method of valuing Regencell Bioscience by comparing valuation metrics of similar companies.Regencell Bioscience is currently under evaluation in return on equity category among its peers.
Regencell Bioscience ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Regencell Bioscience's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Regencell Bioscience's managers, analysts, and investors.Environmental | Governance | Social |
Regencell Fundamentals
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.28 | ||||
| Current Valuation | 65.65 M | ||||
| Shares Outstanding | 13.01 M | ||||
| Shares Owned By Insiders | 88.81 % | ||||
| Shares Owned By Institutions | 0.19 % | ||||
| Number Of Shares Shorted | 62.16 K | ||||
| Price To Earning | 26.21 X | ||||
| Price To Book | 8.95 X | ||||
| EBITDA | (3.62 M) | ||||
| Net Income | (4.36 M) | ||||
| Cash And Equivalents | 59.41 K | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 85.74 K | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 13.94 X | ||||
| Book Value Per Share | 0.63 X | ||||
| Cash Flow From Operations | (4 M) | ||||
| Short Ratio | 0.31 X | ||||
| Earnings Per Share | (0.33) X | ||||
| Price To Earnings To Growth | 2.15 X | ||||
| Number Of Employees | 12 | ||||
| Beta | -0.6 | ||||
| Market Capitalization | 73.52 M | ||||
| Total Asset | 8.44 M | ||||
| Retained Earnings | (21.62 M) | ||||
| Working Capital | 7.92 M | ||||
| Current Asset | 438.2 M | ||||
| Current Liabilities | 551.3 M | ||||
| Five Year Return | 4.37 % | ||||
| Net Asset | 8.44 M |
About Regencell Bioscience Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Regencell Bioscience Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Regencell Bioscience using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Regencell Bioscience Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 214.1 M | 224.8 M | |
| Cost Of Revenue | 745.6 K | 708.3 K | |
| Sales General And Administrative To Revenue | 0.02 | 0.04 | |
| Capex To Revenue | 0.07 | 0.04 | |
| Revenue Per Share | 23.27 | 22.10 | |
| Ebit Per Revenue | 0.10 | 0.12 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Regencell Bioscience offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regencell Bioscience's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regencell Bioscience Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regencell Bioscience Holdings Stock:Check out Regencell Bioscience Piotroski F Score and Regencell Bioscience Altman Z Score analysis. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regencell Bioscience. If investors know Regencell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regencell Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.33) | Return On Assets (0.28) | Return On Equity (0.43) |
The market value of Regencell Bioscience is measured differently than its book value, which is the value of Regencell that is recorded on the company's balance sheet. Investors also form their own opinion of Regencell Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Regencell Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regencell Bioscience's market value can be influenced by many factors that don't directly affect Regencell Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regencell Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Regencell Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regencell Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.